Skip to main content
$0.54 -$0.02 (-3.3%)

03:59 PM EDT on 05/19/22

Windtree Therapeutics Inc Com (NASDAQ:WINT)

CAPS Rating: No stars

A biotechnology company, which develops its proprietary surfactant technology as Surfactant Replacement Therapies for respiratory disorders and diseases.

Current Price $0.54 Mkt Cap $16.4M
Open $0.54 P/E Ratio 0.00
Prev. Close $0.54 Div. (Yield) $0.00 (0.0%)
Daily Range $0.51 - $0.57 Volume 176,290
52-Wk Range $0.48 - $3.40 Avg. Daily Vol. 1,076,154

Caps

How do you think NASDAQ:WINT will perform against the market?

Add Stock to CAPS Watchlist

All Players

302 Outperform
34 Underperform
 

All-Star Players

23 Outperform
11 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:WINT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

grahamfordummies (< 20)
Submitted December 30, 2013

Valuation already anticipates slow launch for Surfaxin (infant respiratory distress syndrome or RDS), but is missing the game changer development of Aerosurf (aerosolized inhalation, also for infant RDS, but avoids the intubation required for… More

californiasun (< 20)
Submitted August 24, 2011

History always seems to repeats itself...

Recent Community Commentary

Read the most recent pitches from players about WINT.

Recs

0
Member Avatar bryanhenry (< 20) Submitted: 5/17/2015 11:08:48 PM : Outperform Start Price: $13.16 NASDAQ:WINT Score: -179.36

shooting to the moon

Recs

0
Member Avatar dividendum (< 20) Submitted: 3/14/2014 12:25:48 PM : Outperform Start Price: $31.43 NASDAQ:WINT Score: -208.52

The biotechnology field is on the rise. Big things are to come.

Recs

1
Member Avatar grahamfordummies (< 20) Submitted: 12/30/2013 3:54:45 PM : Outperform Start Price: $31.66 NASDAQ:WINT Score: -210.12

Valuation already anticipates slow launch for Surfaxin (infant respiratory distress syndrome or RDS), but is missing the game changer development of Aerosurf (aerosolized inhalation, also for infant RDS, but avoids the intubation required for Surfaxin and all competition). Recent financing extends cash runwat through Surfaxin launch and aerosurf 2b studies in mid 15. Attractive target.

Leaderboard

Find the members with the highest scoring picks in WINT.

Score Leader

DeadmanLiving

DeadmanLiving (73.15) Score: +467.49

Even a blind rat finds cheese every now and again.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
DeadmanLiving 73.15 4/15/2009 10/20/2009 Underperform 1Y $470.61 -99.89% +367.60% +467.49 0 Comment
anticitradeshort 27.88 9/30/2009 Underperform NS $342.30 -99.84% +266.10% +365.94 0 Comment
californiasun < 20 8/24/2011 Underperform 3W $27.86 -98.06% +235.09% +333.16 1 Comment
bioman100 < 20 8/25/2006 Underperform NS $373.80 -99.86% +220.36% +320.21 1 Comment
IdahoInvestor 28.00 12/16/2011 Underperform 5Y $21.04 -97.43% +219.54% +316.98 0 Comment
HunterNumber9 75.95 12/30/2010 Underperform 5Y $52.78 -98.98% +209.52% +308.50 0 Comment
mjb1977 69.41 12/29/2010 Underperform 5Y $53.20 -98.98% +208.64% +307.62 0 Comment
leemanschmidt 95.81 10/12/2006 Underperform 3W $514.52 -99.90% +203.71% +303.60 0 Comment
Sillitoe < 20 2/11/2008 Underperform NS $495.60 -99.89% +202.85% +302.74 0 Comment
allmymarbles 59.19 2/24/2011 Underperform 5Y $28.14 -98.08% +197.51% +295.59 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for WINT.